Thus, cultured human CD34+ cell administration improved the phenotype of diabetic nephropathy (urinary albumin excretion and pathological damage), enhanced anti-inflammatory and angiogenic gene expression in kidney tissue, and modified carbohydrate metabolic pathways in a rat model of STZ-induced diabetic nephropathy. This evidence concerns the gene CD34 and diabetic kidney disease.